Cargando…
CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease
The exact mechanism of glatiramer acetate (GA, Copaxone®), an FDA-approved immunomodulatory therapy for multiple sclerosis (MS), remains unclear after decades of research. Previously, we have shown that GA therapy of MS induces CD8(+) T cell responses that can potentially suppress pathogenic CD4(+)...
Autores principales: | Tyler, Andrew F., Mendoza, Jason P., Firan, Mihail, Karandikar, Nitin J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689655/ https://www.ncbi.nlm.nih.gov/pubmed/23805274 http://dx.doi.org/10.1371/journal.pone.0066772 |
Ejemplares similares
-
Neuroantigen-Specific Autoregulatory CD8+ T Cells Inhibit Autoimmune Demyelination through Modulation of Dendritic Cell Function
por: Kashi, Venkatesh P., et al.
Publicado: (2014) -
Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018) -
EBV-specific CD8 T lymphocytes and B cells during glatiramer acetate therapy in patients with MS
por: Guerrera, Gisella, et al.
Publicado: (2020) -
Therapeutic intervention in relapsing autoimmune demyelinating disease through induction of myelin-specific regulatory CD8 T cell responses
por: Brate, Ashley A., et al.
Publicado: (2019) -
Suppression of autoimmune demyelinating disease by preferential stimulation of CNS-specific CD8 T cells using Listeria-encoded neuroantigen
por: Itani, Farah R., et al.
Publicado: (2017)